Search here:

Acquisition of Zentiva by Advent

Advisor to Advent on the acquisition of Zentiva, the European generics business of Sanofi

 

Date: 2018

Country: Czech Republic (HQ), France, Germany, Great Britain, Italy, Romania, Poland, Slovakia and other European countries

Industry: Pharmaceuticals

Target: Zentiva

Buyer (client): Advent

Seller: Sanofi

VCP’s role/competence: buy-side M&A advisor

  • VCP acted as local M&A advisor to Advent on the €1.9bn acquisition of Zentiva, the European generics business of Sanofi, the international pharmaceutical manufacturer
  • Zentiva was carved out by Sanofi after the strategic decision to refocus from generic drugs
  • The sale was organised as open auction and attracted the interest of numerous international strategic players and financial sponsors
  • VCP supported Advent by covering the main markets of Zentiva, by providing crucial market intelligence gathered through our local contact network and by researching for potential add-on opportunities in the CEE region
  • The transaction was closed in September 2018

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close